+

WO2006100679A3 - Recombinant antibodies against human type ii transglutaminase and uses thereof - Google Patents

Recombinant antibodies against human type ii transglutaminase and uses thereof Download PDF

Info

Publication number
WO2006100679A3
WO2006100679A3 PCT/IL2006/000368 IL2006000368W WO2006100679A3 WO 2006100679 A3 WO2006100679 A3 WO 2006100679A3 IL 2006000368 W IL2006000368 W IL 2006000368W WO 2006100679 A3 WO2006100679 A3 WO 2006100679A3
Authority
WO
WIPO (PCT)
Prior art keywords
transglutaminase
antibodies against
against human
recombinant antibodies
human type
Prior art date
Application number
PCT/IL2006/000368
Other languages
French (fr)
Other versions
WO2006100679A2 (en
Inventor
Roberto Marzari
Daniele Sblattero
Original Assignee
Quark Biotech Inc
Qbi Entpr Ltd
Roberto Marzari
Daniele Sblattero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc, Qbi Entpr Ltd, Roberto Marzari, Daniele Sblattero filed Critical Quark Biotech Inc
Publication of WO2006100679A2 publication Critical patent/WO2006100679A2/en
Publication of WO2006100679A3 publication Critical patent/WO2006100679A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides specific antibodies that are able to inhibit TGase II enzymatic activity. The present invention further provides a pharmaceutical composition comprising as an active ingredient the antibody of the invention useful in treating or preventing fibrosis diseases, scarring, or fibrosis-related pathologies. The pharmaceutical composition may be useful for treating both acute and chronic forms of fibrosis of organs.
PCT/IL2006/000368 2005-03-22 2006-03-22 Recombinant antibodies against human type ii transglutaminase and uses thereof WO2006100679A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66423805P 2005-03-22 2005-03-22
US60/664,238 2005-03-22
US68900605P 2005-06-08 2005-06-08
US60/689,006 2005-06-08

Publications (2)

Publication Number Publication Date
WO2006100679A2 WO2006100679A2 (en) 2006-09-28
WO2006100679A3 true WO2006100679A3 (en) 2007-03-29

Family

ID=37024230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000368 WO2006100679A2 (en) 2005-03-22 2006-03-22 Recombinant antibodies against human type ii transglutaminase and uses thereof

Country Status (1)

Country Link
WO (1) WO2006100679A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105302A1 (en) * 2009-03-19 2010-09-23 Queensland University Of Technology Targets for growth factor signalling and methods of therapy
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
GB201209096D0 (en) * 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
US20250019463A1 (en) 2021-11-18 2025-01-16 UCB Biopharma SRL Method for the treatment of progressive chronic interstitial lung disease
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (en) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (en) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARZARI R. ET AL.: "Molecular Dissection of the Tissue Transglutaminase Autoantibody Response in Celiac Disease", THE JOURNAL OF IMMUNOLOGY, vol. 166, 2001, pages 4170 - 4176, XP003009550 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2006100679A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2007109221A3 (en) Methods for reducing protein aggregation
EP2175834B8 (en) Glp-1-fc fusion protein formulation
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2006119467A3 (en) Protein activity modification
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006110819A3 (en) Variant forms of urate oxidase and use thereof
WO2007011693A3 (en) Compositions of placentally-derived stem cells for the treatment of cancer
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
PL384263A1 (en) Variant of urate oxidase and its application
WO2007092312A3 (en) Topical skin treating compositions
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2006111524A3 (en) Il-21 variants
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2008011559A3 (en) Synthetic lung surfactant and use thereof
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2008143705A3 (en) Methods and compositions for rapid inactivation of proteins
WO2007089334A3 (en) Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06711341

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6711341

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载